Chemistry:Omiloxetine
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C27H25F2NO4 |
| Molar mass | 465.497 g·mol−1 |
| 3D model (JSmol) | |
| Density | 1.3±0.1 g/cm3 |
| Melting point | 228.65 °C (443.57 °F) |
| Boiling point | 587.2 °C (1,089.0 °F) |
| Solubility in water | 0.0015 mg/mL (20 °C) |
| |
| |
Omiloxetine (omiloextinum, omiloxetino INN)[1] was a selective serotonin reuptake inhibitor drug candidate that underwent preclinical development by the Spanish pharmaceutical company, Ferrer Internacional, until 2005, when it was abandoned.[2][3]
Rafael Foguet also patented Abaperidone.
References
- ↑ "Proposed INN: List 76". WHO Drug Information 10 (4): 212–213. 1996. https://www.who.int/medicines/publications/druginformation/innlists/PL76.pdf.
- ↑ "Omiloxetine - Ferrer licensing offer, worldwide". R & D Focus Drug News. 2005-12-05. http://business.highbeam.com/436989/article-1G1-139327925/omiloxetine-ferrer-licensing-offer-worldwide.
- ↑ "Omiloxetine - Ferrer partnering opportunity, worldwide Ferrer preclinical data". R & D Focus Drug News. 2003-12-08. http://business.highbeam.com/436989/article-1G1-110935603/omiloxetine-ferrer-partnering-opportunity-worldwide.
 |  |
